Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Brave SR, et al. Among authors: ashton s. Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25. Mol Cancer Ther. 2011. PMID: 21441409 Free article.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST. Floc'h N, et al. Among authors: ashton s. Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872381
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.
Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr. Oser MG, et al. Among authors: ashton s. Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29. Cancer Discov. 2019. PMID: 30373918 Free PMC article.
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST. Ashton S, et al. Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355. Sci Transl Med. 2016. PMID: 26865565 Free article.
ZD6126: a novel small molecule vascular targeting agent.
Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. Blakey DC, et al. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502. doi: 10.1016/s0360-3016(02)03922-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459377
140 results